| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human C3/C3b |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于C3/C3b抗体的模拟参考文献示例(内容为虚构，仅用于示例格式)：
1. **"Targeting C3 with monoclonal antibody ameliorates complement-mediated tissue injury"**
- 作者：Smith A, et al.
- 摘要：研究了一种靶向C3的单克隆抗体在抑制补体过度激活中的作用，通过动物模型证明其可减轻缺血-再灌注损伤和炎症反应，为治疗补体相关疾病提供新策略。
2. **"Compstatin-based C3 inhibition in paroxysmal nocturnal hemoglobinuria: a phase II clinical trial"**
- 作者：Lambris JD, et al.
- 摘要：报道了Compstatin衍生物(C3靶向肽类抑制剂)在阵发性睡眠性血红蛋白尿(PNH)患者中的临床试验结果，显示其显著减少溶血事件并改善患者生活质量。
3. **"Structural basis of C3b recognition by a therapeutic antibody for age-related macular degeneration"**
- 作者：Wang Y, et al.
- 摘要：通过冷冻电镜解析了抗C3b抗体与C3b的复合物结构，揭示了抗体阻断补体旁路途径激活的分子机制，为AMD治疗提供理论支持。
4. **"C3 glomerulopathy treated with anti-C3 antibody: a case series analysis"**
- 作者：Zhang R, et al.
- 摘要：分析抗C3抗体在C3肾小球病中的治疗效果，表明其可降低尿蛋白水平并延缓肾功能恶化，提示靶向补体系统的潜在临床价值。
(注：以上文献为虚构示例，实际引用需查询真实数据库如PubMed、ScienceDirect等。)
C3 and C3b antibodies are essential tools for studying the complement system, a critical component of innate immunity. C3. a central protein in the complement cascade, undergoes proteolytic cleavage into C3a and C3b during activation. C3b plays a pivotal role in opsonization, phagocyte recruitment, and formation of the membrane attack complex (MAC). Antibodies targeting C3 or its cleavage product, C3b, are widely used to detect complement activation, monitor disease states, and investigate molecular mechanisms in immune responses.
C3 antibodies typically recognize epitopes present in both native C3 and its fragments, while C3b-specific antibodies distinguish the conformationally altered form generated after cleavage. These antibodies enable researchers to differentiate between inactive precursors and activated components, aiding in the analysis of complement pathway engagement. For example, C3b deposition on pathogens or host tissues can be visualized using immunofluorescence or immunohistochemistry, providing insights into infection or autoimmune processes.
Clinically, C3/C3b antibodies are employed in diagnostics for conditions like systemic lupus erythematosus (SLE), glomerulonephritis, and age-related macular degeneration, where dysregulated complement activity contributes to pathology. They also support therapeutic development, such as monitoring complement inhibitor efficacy. Technical applications include Western blotting, ELISA, and flow cytometry, with careful validation required to ensure specificity due to structural similarities between C3 and its derivatives. Overall, these antibodies are indispensable for unraveling complement dynamics in health and disease.
×
